As of the date of this press release, Jyong Biotech does not have any approved drug products available for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory ...
Boost ROI through pharma-diagnostic collaborations, AI-driven analytics, multi-omics investment, and co-developed companion diagnostics and targeted therapies.Dublin, Oct. 15, 2026 (GLOBE NEWSWIRE) -- ...
Siren Biotechnology, a clinical-stage biotechnology company pioneering Universal AAV Immuno-Gene Therapy for cancer, today ...
Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma ...
VERAXA has since generated new spheroid data demonstrating consistent predictivity of T cell engagement specificity across diverse cancer cell lines and validating the model for IND-enabling studies, ...
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Biotech and pharma organizations are adopting AI at rapid pace, focusing on R&D, and precision medicine. As challenges emerge ...
While biotech increasingly adopts AI for R&D, manufacturing bottlenecks constrain health innovation. AI and robotics have the ...
These are far from the only examples of inventing-around, which is rapidly becoming a central feature in biotech drug development. Others include the tumor necrosis factor (TNF) inhibitors for RA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results